Frost & Sullivan Independent Equity Research

RedHill Biopharma: Net revenues for 2017 totaled $4M, and met our expectations. We expect Redhill to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; Price target raised to NIS 2.59


Company: RedHill Biopharma        

Sector: Pharmaceuticals

Report type: Annual Report

Published on: 11 March, 2018

RedHill research articles: